藥明系股價全線反彈 藥明合聯(02268.HK)回升7.5%
藥明系股價今天(6日)全面反彈,尤其是上市不足一個月的藥明合聯(02268.HK)由上市高位連跌兩天後,今天重拾升勢,最高見30.4元,現報29.5元,回升7.5%。藥明巨諾-B(02126.HK)重越10天線(3元),最高見3.32元,現報3.18元,回升6.7%。
「藍籌新貴」藥明康德(02359.HK)高見84.1元,現報82.5元,回升1.9%。擬回購最多6億美元股份的藍籌藥明生物(02269.HK)扭兩連跌,股價由逾三年半低位反彈,最高見32.15元,現報30.7元,回升1.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.